160 research outputs found
Perceptual-cognitive skills and expert performance in sailing
Savelsbergh, G.J.P. [Promotor]Cañal-Bruland, R. [Copromotor
Electroconvulsive therapy for severe depression:Improving efficacy and preventing relapse
We determined predictors of the efficacy of ECT and predictors of relapse after successful ECT. In addition, we investigated whether the addition of nortriptyline to a course of ECT enhances its efficacy and prevents relapse after successful ECT
Clinical characteristics associated with relapse 2 years after electroconvulsive therapy for major depression
Objective: High relapse rates are observed after electroconvulsive therapy (ECT) for major depression. Identifying patients who are at increased risk for relapse to intensify their treatment regimen post-ECT might reduce relapse rates. We aimed to determine clinical characteristics that are associated with relapse within 2 years after successful ECT. Methods: Patients who remitted to ECT in a randomised controlled trial comparing adjuvant nortriptyline and placebo during a course of bilateral ECT were followed-up prospectively for 1 year with open-label nortriptyline (Dutch Trial Register NTR5579). Second-year follow-up data were collected retrospectively. Thirty-four patients were included in this follow-up cohort. To examine the association between clinical characteristics and the risk of relapse, unadjusted hazard ratios (HRs) were calculated. Results: At 2 years post-ECT, the overall relapse rate was 50%, and the HRs for relapse in patients with psychotic features, a higher severity of depression, and medication resistance prior to ECT were 0.33 (CI 0.12–0.89; p = 0.029), 0.88 (CI 0.80–0.98; p = 0.014), and 4.48 (CI 1.28–15.73, p = 0.019), respectively. No effect was found for age, sex or episode duration on the relapse rate. Conclusions: Depressed patients with psychotic features, with higher symptom severity and without medication resistance prior to ECT have a significantly decreased risk of relapse after successful ECT. A sustained remission rate of 50% over 2 years in patients with severe major depression who were treated with nortriptyline monotherapy after successful ECT is encouraging.</p
Influence of an adjuvant antidepressant on the efficacy of electroconvulsive therapy: A systematic review and meta-analysis
Objective: The primary indication for electroconvulsive therapy is medication-resistant major depression. There is some evidence that combining electroconvulsive therapy with an antidepressant, instead of electroconvulsive therapy monotherapy, might improve remission rates. However, data on this topic have not been systematically studied. We undertook a systematic review and meta-analysis to determine the effectiveness of an adjuvant antidepressant during electroconvulsive therapy for major depression. Methods: Embase, Medline Ovid, Web of Science, Cochrane Central, PsychINFO Ovid and Google Scholar were searched up to January 2019. Randomized controlled trials and cohort studies reporting on the influence of an adjuvant antidepressant on the efficacy of electroconvulsive therapy for major depression were included. Authors independently screened records, extracted data and assessed study quality. We reported this systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: Nine studies were included in the meta-analysis. The meta-analysis revealed a significant advantage of adjuvant antidepressants versus placebo. The overall effect size per category of antidepressant was as follows: tricyclic antidepressants: Hedges’ g 0.32 (95% confidence interval: [0.14, 0.51]) (k = 6) with low heterogeneity (I2: 4%, p = 0.39); selective serotonin reuptake inhibitors/serotonin noradrenaline reuptake inhibitors: Hedges’ g 0.27 (95% confidence interval: [0.03, 0.52]) (k = 2) with a lack of heterogeneity (I2: 0%, p = 0.89); and monoamine oxidase inhibitors: Hedges’ g 0.35 (95% confidence interval: [−0.07, 0.77]) with moderate heterogeneity (I2: 43%, p = 0.17) (k = 3). Conclusion: An adjuvant antidepressant enhances the efficacy of electroconvulsive therapy for major depression. Tricyclic antidepressants, selective serotonin reuptake inhibitors/serotonin noradrenaline reuptake inhibitors and monoamine oxidase inhibitors showed the same effect size. However, the effect sizes of tricyclic antidepressants and monoamine oxidase inhibitors are most likely underestimated, due to insufficient doses in most of the included studies. We recommend the routine use of an adequately dosed antidepressant during electroconvulsive therapy for major depression
Commentary: Long-term Practice with Domain-Specific Task Constraints Influences Perceptual Skills
Beta-Blocking Agents and Electroconvulsive Therapy
In this review we want to summarize the results of the placebo-controlled randomized clinical trials with betablocking
adrenergic agents during electroconvulsive therapy (ECT), and review the effect on seizure duration and cardiovascular
variables. We sea
A biographical approach to studying individual change and continuity in walking and cycling over the life course
Most research studies seeking to understand walking and cycling behaviours have used cross-sectional data to explain inter-individual differences at a particular point in time. Investigations of individual walking and cycling over time are limited, despite the fact that insights on this could be valuable for informing policies to support life-long walking and cycling. The lack of existing longitudinal data, difficulties associated with its collection and scepticism towards retrospective methods as a means to reconstruct past behavioural developments have all contributed to this deficit in knowledge. This issue is heightened when the time frame extends to longer term periods, or the life course in its entirety. This paper proposes and details a retrospective qualitative methodology that was used to study individual change and stability in walking and cycling within a life course framework. Biographical interviews supported by a life history calendar were developed and conducted with two adult birth cohorts. Interpretive, visual biographies were produced from the interview materials. Analysis focused on identifying the occurrence, context and timing of behavioural change and stability over the life course. Typologies of behavioural development were generated to resolve common and distinct behavioural patterns over the life course. Whilst the validity of reconstructed biographies of walking and cycling cannot be proven, this is an approach which offers credible and confirmable insights on how these behaviours increase, diminish, persist, cease, are restored or adapted through the life course, and how behavioural trajectories of walking and cycling may be evolving through historical time
Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation
BACKGROUND: Spinal cord stimulation (SCS) has been shown to be effective in the management of certain neuropathic pain conditions, however, the underlying mechanisms are incompletely understood. In this study, we investigated repetitive SCS in a rodent neuropathic pain model, revealing long-lasting and incremental attenuation of hyperalgesia and a mechanism of action involving endocannabinoids. METHOD: Animals were implanted with monopolar electrodes at the time of partial sciatic nerve injury. Dorsal columns at spinal segments T12/13 were stimulated 3 days later (early SCS), and again at day 7 (late SCS) using low-frequency parameters. Hypersensitivity to cutaneous mechanical stimuli was assessed using von Frey filaments. Pharmacological agents, selected to identify endocannabinoid and opioid involvement, were administered intraperitoneally, 10 min before SCS. RESULTS: Early SCS caused partial reversal of mechanical hypersensitivity with corresponding changes in the biomarker of central sensitization, [phospho-Tyr1472 ]-GluN2B. The partial reversal of hyperalgesia by early SCS was amplified by co-administration of LY 2183240, an inhibitor of endocannabinoid reuptake/breakdown. This amplification was inhibited by a CB1 R antagonist, AM251, but not by a CB2 R antagonist, AM630. Early SCS-induced reversal of hyperalgesia was attenuated by naloxone, indicating a role for opioids. Late SCS resulted in an incremental level of reversal of hyperalgesia, which was inhibited by AM251, but not by CB2 or opioid receptor antagonists. CONCLUSION: The endocannabinoid system, and in particular the CB1 R, plays a pivotal role in the long-lasting and incremental reversal of hyperalgesia induced by repetitive SCS in a neuropathic pain model
- …